Kadar Lipoprotein (a) dan Kadar high Sensitivity C-Reaktif Protein pada Penderita Penyakit Jantung Koroner Yang Dilakukan Angiografi
DAFTAR PUSTAKA
1.
World Health Organization, WHO World Health Organization Report
2000, Genewa: WHO; (2001)
2.
World Health Organization. Deaths from Coronary Heart Disease.
(2008).
Available
from
http://www.who.int/mediacentre/factsheets/fs310/en/index.html
3.
Deitcher SR, Rodgers GM.Thrombosis and antithrombotic therapy. In :
Greer JP, Foerster J, Lukens JN, et al. Wintrobe`s Clinical Hematology.
11th ed. Lippincott Williams and Wilkins. USA. 2004:1714-18.
4.
Manurung D.Patogenesa terkini dari Sindroma Koroner Akut. Prosiding
Simposium Pendekatan Holistik Penyakit Kardiovaskuler II. Balai
Penerbit Bagian Ilmu Penyakit Dalam FK UI. Jakarta. 2003; 63-69.
5.
Guran O, Akalin F, Ayabakan C, et al.High-sensitivity C-reactive protein
in children at risk for coronary arterydisease. Acta Pediatrica.
2007:96;1214-1219
6.
Libby P. The Pathogenesis of atherosclerosis. In : Kasper D, Braunwald
E, Fauci A,et al.ed. Harrison’s Principles of Internal Medicine,16th eds.
Mc Graw Hill. 2005;1425-1429
7.
Kasap S, Gonenc A, Sener D.E. and Hisar I.Serum cardiac markers in
patients with acute myocardialinfarction: oxidative stress, C-Reactive
protein
and
Nterminalprobrain
natriuretic
peptide.
Journal
of
ClinicalBiochemistry and Nutrition. 2007: 41; 50-57.
8.
Mannering D, Bennet ED, Ward DE, Dawkins K, Valentine H, et al.
Accurate detection of triple vessel disease in patients with exercise
Universitas Sumatera Utara
induced ST segment depression after infarction. Br Heart J. 1987: 57;
133-8
9.
Majid A. Penyakit jantung koroner : patofisiologi, pencegahan dan
pengobatan terkini. Pidato pengukuhan guru besar tetap dalam bidang
ilmu Fisiologi pada Fakultas Kedokteran Universitas Sumatera Utara.
USU press. 2007
10. Raymond J. Gibbons, Jonathan Abrams, Kanu Chatterjee, Jennifer
Daley, Prakash C. Deedwania
et al.Guideline
Update
for
the
Management of Patients With Chronic Stable Angina. ACC/AHA 2002.
Available
from
http://www.cardiosource.com/guidelines/guidelines/stable/stable
11. Gibbons RJ. ACC/AHA 2002 guideline update for the management of
patients with chronic stable angina --summary article : a report of the
american college of cardiology/american heart association task force on
practice guidelines
(committee on the management of patients with
chronic stable angina). Circulation. 2003:107; 149-158
12. Peer A, Falkensammer G, Alber H, Kroiss A, Griesmacher A, Ulmer H,
Pachinger O, Mair J. Limited utilities of N-terminal pro B-type natriuretic
peptide and other newer risk markers compared with traditional risk
factors for prediction of significant angiographic lesions in stable
coronary artery disease. Heart. 2009:95; 297–303
13. Maria Drakopoulou, Konstantinos Toutouzas, Elli Stefanadi et al.
Association of inflammatory markers with angiography severity and
extent of coronary artery disease. Atherosclerosis. 2009: 206; 335-39
Universitas Sumatera Utara
14. Valentin Fuster, R. Wayne Alexander, Robert A. O' Rourke. Cardiac
catheterization, cardiac angiography and coronary blood flow and
pressure measurements. In Hurst's The Heart. 2004:17; 483-537
15. Hansson GK. Inflammation, atherosclerosis, and coronary artery
disease. N Engl J Med. 2005:352; 1685-95
16. Ross R. Atherosclerosis - an inflammatory disease, N Eng J Med. 1999:
340; 115–26
17. Packard RRS, Libby P. Inflammation in atherosclerosis: from vascular
biology to biomarker discovery and risk prediction. Clinical Chemistry.
2008:54; 24-38.
18. Buffon A, Biasucci LM, Liuzzo GD, Onofrio G, CreaFand Maseri A.
Widespread coronary inflammationin unstable angina. The New England
Journal of Medicine. 2002:347; 5-12.
19. Thakur S, Gupta S, Parchwani H, Shah V, Yadav V (2011).Hs-CRP: a
potential marker for coronary heart disease. Indian Journal of
Fundamental and Applied Life Science. 2011:1; 1-4
20. Razzouk L. C-reactive protein predicts long-term mortality independently
of
low-density
lipoprotein
cholesterol
in
patients
undergoing
percutaneous coronary intervention. Am Heart J. 2009: 158; 277-83
21. Daniel G, Hackam Sonia S. Anand. Emerging risk factors for
atherosclerotic disease: A critical review of the evidence. Journal of
American Heart Association. 2003:290; 932-940.
22. Ridker PM. C-Reactive Protein a simple test to help predict risk of heart
attack and stroke. Circulation. 2003:108; 81-85
Universitas Sumatera Utara
23. Marcovina SM, Koschinky ML. Lipoprotein(a) as a risk factor for coronary
artery disease. American J Cardiology. 1998: 82; (12A)
24. Scanu AM. The role of Lipoprotein(a) in the pathogenesis of
atherosclerotic cardiovascular disease and its utility as predictor of
coronary heart disease events. Curr Cardiol Rep. 2001:3(5); 385-90
25. Dahlen GH. Incidence of lipoprotein(a) among population, in Scanu AM.
Ed. Lipoprotein(a). San Diego Toronto,Tokyo, American press Inc.
1990;183-204
26. Nagayama M, Yukito S, Nagayama T.Lipoprotein(a) and ischemic
cerebrovascular disease in young adult. Stroke. 1994:25; 74-8
27. Uterman G. The misteri of lp(a). Science. 1989:246; 904-10
28. Shahid HS. Serum high-sensitivity C-reactive protein and lipoprotein(a)
levels: a comparison between diabetic and non-diabetic patients with
coronary artery disease. Med J Malaysia. 2011: 66; 113-116
29. Hasnat MA, Islam Aemm, Chowdhury AW, Khan Hilr, Hosan MZ. High
sensitivity
C-reactive
protein
(hs-CRP)
and
its
correlation
with
angiographic severity of patient with coronary artery disease. J Dhaka
Med Coll. 2010:19; 91-97
30. Jalali BA, Rafie M, Mozaffari H. Lipoprotein(a) as a strong risk factor for
coronary artery disease in iranian population. Medical Journal of Islamic.
2000:13; 5-9
31. Achar SA, Kundu S, Norcross WA. Diagnosis of acute coronary
syndrome. American Family Physician 2005:72(01); 119-126
Universitas Sumatera Utara
32. Bucova M and Nikolitsa Pappa. C - Reactive protein, cytokines and
inflammation in cardiovascular disease. Bratis1 Lek Listy. 2008:109; 33340
33. Eleni S. Nakou ES, Evangelos N. Liberopoulos et al. The role of Creactive protein in atherosclerotic cardiovascular disease: an overview.
Current Vascular Pharmacology. 2008:6;258-70
34. McGill HC, McMahan CA, Herderick EE, Malcom GT, Tracy RE, Strong
JP. (2000). Origin of atherosclerosis in childhood and adolescence. Am J
Clin Nutr. 2000:72; 1307S-15S
35. Desideri G, De Simone M et al. Early activation of endothelial cells and
platelets in obesitas children. J Clin Endocrinol Metab. 2005:90; 3145-52
36. Kavazarakis E, Moustaki M, Gourgiotis D. The impact of serum lipid
levels on circulating soluble adhesion molecules in childhood. Pediatr
Res. 2002:52; 454-8
37. Koenig W. C-reactive protein and cardiovascular risk: an update on what
is going on in cardiology. Nephrol Dial Transplant. 2003:18; 1039–41
38. Wangko LC, Budiono B, Lefrandt RL. Angiografi koroner indikasi,
kontraindikasi, dan proteksi terhadap radiasi. J Biomedik. 2012;4(3)
Abstrak
39. Scanu AM. Structural and functional polymorphism of lipoprotein(a)
biological and clinical implications. Clinical Chemistry. 1995:41(1);170-2.
NACB Symposium
40. Hajjar KA, Nachman RL. The role of lipoprotein(a) in atherogenesis and
thrombosis. Anna Rev Med.1996
Universitas Sumatera Utara
41. Butman BT, Taddei-Peters WC, Ransom JH.
Lipoprotein(a)
as a
marker for atherosclerotic disease. Clinical Hemostasis review. 1993
42. Scanu AM, Fless GM. Lipo (a) heterogenicity and biological relevance. J
clinical Invest. 1990:85; 1709-15
43. Berg K. Lp(a) Lipoprotein : an overview, In : Scanu AM. Lipoprotein(a).
Academic press inc. San Diego,Toronto.Tokyo. 1990; 1-20
44. Ridker PM. Plasma concentration of lipoprotein and the risk of
future.Stroke. JAMA. 1995; 273
45. Scanu AM. Lipoprotein(a) and atherosclerosis. Annals of Internal
Med.1991:115; 209-18
46. Scott J. Lipoprotein(a) Thrombotic and atherogenic. BMJ. 1995:303; 6634
47. Galton J, Krone W. Hyperlipidaemia in Practice. Gower Medical
Publishing. London. 8-9.1991
48. Borque L. Automated Latex Nephelometric Immunoassay for the
Measurement of Serum Lipoprotein(a). Journal Clin Lab Anal. 1993: 7(2);
105-10
49. William RH. Radioimmunoassay of human plasma Lp(a) lipoprotein.
Journal of Lipid Research. 1997:18; 331-338
50. Nguyen TT. Predictive value of electrophoretically detected lipoprotein(a)
for coronary heart disease and cerebrovascular disease in a communitybased cohort of 9936 men and women. Circulation. 1997:96; 1390-1397.
51. Torres MB.Rapid Detection of Elevated Serum Lipoprotein(a) Levels :
Aubiodot Lp(a). Medical Education Cooperation with Cuba. 2000
Universitas Sumatera Utara
52. Stanley J. Instrumentation. In : Stanley J (eds). Essentials of
Immunology & Serology. Thomson Delmar Learning. Columbia. 2002;
133-48
53. Libby P, Ridker PM. Inflammation and atherosclerosis: role of creactive
protein in risk assessment. Am J Med. 2004:116; 9-16
54. Vermeire S,Van Assche G,Rutgeerts P. C-reactive protein as a marker
for inflammatory bowel disease. Inflammatory Bowel Diseases. 2004:10;
661-5.
55. Meier-Ewert HK, Ridker PM, Rifai N. Absence of diurnal variation of
Creactive protein concentrations in healthy human subjects.Clin Chem.
2001:47; 426–430
56. Gotschlich E. C-reactive protein: a historical overview. Annals of the New
York Academy of Sciences. 1989:557; 9-18.
57. Zakynthinos E, Pappa N. Inflammatory biomarkers in coronary artery
disease. Journal of Cardiology. 2009:53; 317-33
58. Danesh J, Pepys MB. C-Reactive protein and coronary disease: is there
a causal link?. Circulation. 2009:120; 2036-39
59. Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB . C-reactive
protein and coronary heart disease: a critical review. J Intern Med. 2008:
264; 295–314
60. Ridker P, Rifai N, Rose L. Comparison of c-reactive protein and lowdensity
lipoprotein
cholesterol
levels
in
the
prediction
of
first
cardiovascular events. The New England Journal of Medicine. 2002:
347(20); 1557-65.
Universitas Sumatera Utara
61. Delanghe J, Langlois M, De Bacquer D. Discriminative value of serum
amyloid A and other acute-phase proteins for coronary heart disease.
Atherosclerosis. 2002:160(2); 471-6
62. Pearson TA, George A. Mensah. Markers of inflammation and
cardiovascular disease. application to clinical and public health practice a
statement for healthcare professionals from the centers for disease
control and prevention and the american heart association. aha/cdc
scientific statement. Circulation. 2003:107; 499-511.
63. Handojo Indro. Immunoassay Terapan pada Beberapa Penyakit Infeksi.
Ed 1, Airlangga University Press, Surabaya, 2004; 272-285
64. Loho T. Pemeriksaan laboratorium pada stroke. Dalam: Pendidikan
Berkesinambungan Patologi Klinik, ed 1. Penerbit FKUI. 2008; 57-70
65. Henry JB. Clinical Diagnosis and Management by Laboratory Methods,
ed 20, Saunders. Philadelphia. 2001; 259-262
66. Roche. Roche Diagnostic GmbH. CRP. Product Information. 2003
67. Tietz. Clinical Chemistry and Molecular Diagnostics, ed 4. Saunders
Missouri. 2006; 543-546
68. Nyandak T, Gogna A, Bansal S, Deb M. High Sensitive C-Reactive
Protein (hsCRP) and its Correlation with Angiographic Severity of
Coronary Artery Disease (CAD). JIACM. 2007;8(3):217-21
69. Tanuwidjojo S. Recent development in pathogenesis of atherosclerosis.
Dalam: Tanuwidjojo S, Rifqi S. Atherosklerosis From Theory to Clinical
Practice, Naskah lengkap Cardiology-Update, 2003 p13-18
Universitas Sumatera Utara
70. Dwitaryo AB. Endotelium: Target Terapi untuk Penyakit Kardiovaskuler.
Dalam : Tanuwidjojo S, Rifqi S. Atherosclerosis From Theory to Clinical
Practice, Naskah lengkap Cardiology-Update Semarang, 2003 : p71-81
71. Soeharto I. Penyakit Jantung Koroner dan Serangan Jantung. Jakarta:
PT. Gramedia Pustaka Utama; 2004: 61-62
72. Heart-health screenings. American heart association [Internet]. 2011.
[cited 2013 Okt 3]. Available from:
http://www.heart.org/HEARTORG/Conditions/Heart-Health
Screenings_UCM_428687_Article.jsp#.TxegnNUqt0c
73. Price SA. Penyakit aterosklerotik koroner. Dalam: Wijaya C editor.
Patofisiologi Konsep Klinis Proses-Proses Penyakit. Edisi 4. Jakarta:
Penerbit buku kedokteran EGC; 1994:528-556
74. Coronary heart disease risk factors. National Heart Lung and Blood
Institute [Internet]. 2011. [cited 2011 Dec 14]. Available from:
http://www.nhlbi.nih.gov/health/health-topics/topics/hd/atrisk.html
75. Adam JMF . Manfaat penurunan Berat Badan pada Obese dengan
komplikasi Metabolik. Dalam: Djokomoeljanto R, Darmono, Suhartono T,
Pambayun
TGD
PERSADIA dan
editor.
Naskah
Lengkap
Kongres
Nasional
V
PITPERKENI. Semarang: Badan Penerbit UNDIP;
2002: 15-24
76. Patel VB, Robbins MA, Topol EJ. C-reactive protein: A ‘golden marker’
for inflammation and coronary artery disease. Cleveland Clinic J of
Medicine 2001;6(68):521-534.
Universitas Sumatera Utara
77. Azita F, Toba K, Asghar Z. et al. Comparison of lipoprotein(a) and
apolipoproteins in Children with and without familial history of premature
coronary artery disease. Iran J Pediatr, 2008;18 (2):159-162
78. Dutta J, Solankiz US. Lipoprotein(a) and lipid levels in children with
andwithout family history of premature ischemic heartdisease. World
Journal of Pharmacy and Pharmaceutical Sciences,2013; 2 (6): 58115819
79. Murat SN, Karadeniz M, Akyel A, et al. Relationship of high-sensitive Creactive protein with cardiovascular risk factors, clinical presentation and
angiographic profile in patients with acute coronary syndrome: An Indian
perspective. Indian heart journal.2013; 165 : 357-367
80. Cowie, M.R., Dar, Q. The Epidemiologyand Diagnosis of Heart Failure.
In: Fuster,V., et al., eds. Hurst’s the Heart. 12th ed.Volume 1. USA:
McGraw-Hill, 2008: 713
81. Yuliani F, Oenzil F, Iryani D. Hubungan berbagai faktor risiko terhadap
kejadian penyakit jantung koroner pada penderita diabetes mellitus tipe
2. Artikel Penelitian.Jurnal Kesehatan Andalas.2014; 3(1): 37-40
82. Ghodke SS, Padalkar RK, Bhagat SS, Ghone RA, Patil SM. hs- CRP: A
“Golden Marker” of Inflammation and Coronary Artery Disease.
International Journal of Health Sciences & Research. 2012; 2 (6): 42-46
83. Farhan HA, Al-Safar HB. Coronary Artery Disease: Conventional
RiskFactors & Angiographic Findings Among Young Iraqi Adults: Journal
ofBabel; 2010:2:644-650
Universitas Sumatera Utara
84. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease:
risk
factor,
paradox,
and
impact
of
weight
loss.J
Am
Coll
Cardiol.2009;53(21):1925-1932.
85. Jin J. Obesity and the Heart, The definition of obesity is based on body
mass index (BMI),a number calculated from a person’s height and
weight.JAMA. 2013; 310 (19): 2113
86. Karadeniz M, Murat SN, Relationship of high-sensitive C-reactive protein
withcardiovascular risk factors, clinical presentation andangiographic
profile in patients with acute coronarysyndrome: An Indian perspective.
Indian Heart Journal.2013; 65: 357-367
Universitas Sumatera Utara
1.
World Health Organization, WHO World Health Organization Report
2000, Genewa: WHO; (2001)
2.
World Health Organization. Deaths from Coronary Heart Disease.
(2008).
Available
from
http://www.who.int/mediacentre/factsheets/fs310/en/index.html
3.
Deitcher SR, Rodgers GM.Thrombosis and antithrombotic therapy. In :
Greer JP, Foerster J, Lukens JN, et al. Wintrobe`s Clinical Hematology.
11th ed. Lippincott Williams and Wilkins. USA. 2004:1714-18.
4.
Manurung D.Patogenesa terkini dari Sindroma Koroner Akut. Prosiding
Simposium Pendekatan Holistik Penyakit Kardiovaskuler II. Balai
Penerbit Bagian Ilmu Penyakit Dalam FK UI. Jakarta. 2003; 63-69.
5.
Guran O, Akalin F, Ayabakan C, et al.High-sensitivity C-reactive protein
in children at risk for coronary arterydisease. Acta Pediatrica.
2007:96;1214-1219
6.
Libby P. The Pathogenesis of atherosclerosis. In : Kasper D, Braunwald
E, Fauci A,et al.ed. Harrison’s Principles of Internal Medicine,16th eds.
Mc Graw Hill. 2005;1425-1429
7.
Kasap S, Gonenc A, Sener D.E. and Hisar I.Serum cardiac markers in
patients with acute myocardialinfarction: oxidative stress, C-Reactive
protein
and
Nterminalprobrain
natriuretic
peptide.
Journal
of
ClinicalBiochemistry and Nutrition. 2007: 41; 50-57.
8.
Mannering D, Bennet ED, Ward DE, Dawkins K, Valentine H, et al.
Accurate detection of triple vessel disease in patients with exercise
Universitas Sumatera Utara
induced ST segment depression after infarction. Br Heart J. 1987: 57;
133-8
9.
Majid A. Penyakit jantung koroner : patofisiologi, pencegahan dan
pengobatan terkini. Pidato pengukuhan guru besar tetap dalam bidang
ilmu Fisiologi pada Fakultas Kedokteran Universitas Sumatera Utara.
USU press. 2007
10. Raymond J. Gibbons, Jonathan Abrams, Kanu Chatterjee, Jennifer
Daley, Prakash C. Deedwania
et al.Guideline
Update
for
the
Management of Patients With Chronic Stable Angina. ACC/AHA 2002.
Available
from
http://www.cardiosource.com/guidelines/guidelines/stable/stable
11. Gibbons RJ. ACC/AHA 2002 guideline update for the management of
patients with chronic stable angina --summary article : a report of the
american college of cardiology/american heart association task force on
practice guidelines
(committee on the management of patients with
chronic stable angina). Circulation. 2003:107; 149-158
12. Peer A, Falkensammer G, Alber H, Kroiss A, Griesmacher A, Ulmer H,
Pachinger O, Mair J. Limited utilities of N-terminal pro B-type natriuretic
peptide and other newer risk markers compared with traditional risk
factors for prediction of significant angiographic lesions in stable
coronary artery disease. Heart. 2009:95; 297–303
13. Maria Drakopoulou, Konstantinos Toutouzas, Elli Stefanadi et al.
Association of inflammatory markers with angiography severity and
extent of coronary artery disease. Atherosclerosis. 2009: 206; 335-39
Universitas Sumatera Utara
14. Valentin Fuster, R. Wayne Alexander, Robert A. O' Rourke. Cardiac
catheterization, cardiac angiography and coronary blood flow and
pressure measurements. In Hurst's The Heart. 2004:17; 483-537
15. Hansson GK. Inflammation, atherosclerosis, and coronary artery
disease. N Engl J Med. 2005:352; 1685-95
16. Ross R. Atherosclerosis - an inflammatory disease, N Eng J Med. 1999:
340; 115–26
17. Packard RRS, Libby P. Inflammation in atherosclerosis: from vascular
biology to biomarker discovery and risk prediction. Clinical Chemistry.
2008:54; 24-38.
18. Buffon A, Biasucci LM, Liuzzo GD, Onofrio G, CreaFand Maseri A.
Widespread coronary inflammationin unstable angina. The New England
Journal of Medicine. 2002:347; 5-12.
19. Thakur S, Gupta S, Parchwani H, Shah V, Yadav V (2011).Hs-CRP: a
potential marker for coronary heart disease. Indian Journal of
Fundamental and Applied Life Science. 2011:1; 1-4
20. Razzouk L. C-reactive protein predicts long-term mortality independently
of
low-density
lipoprotein
cholesterol
in
patients
undergoing
percutaneous coronary intervention. Am Heart J. 2009: 158; 277-83
21. Daniel G, Hackam Sonia S. Anand. Emerging risk factors for
atherosclerotic disease: A critical review of the evidence. Journal of
American Heart Association. 2003:290; 932-940.
22. Ridker PM. C-Reactive Protein a simple test to help predict risk of heart
attack and stroke. Circulation. 2003:108; 81-85
Universitas Sumatera Utara
23. Marcovina SM, Koschinky ML. Lipoprotein(a) as a risk factor for coronary
artery disease. American J Cardiology. 1998: 82; (12A)
24. Scanu AM. The role of Lipoprotein(a) in the pathogenesis of
atherosclerotic cardiovascular disease and its utility as predictor of
coronary heart disease events. Curr Cardiol Rep. 2001:3(5); 385-90
25. Dahlen GH. Incidence of lipoprotein(a) among population, in Scanu AM.
Ed. Lipoprotein(a). San Diego Toronto,Tokyo, American press Inc.
1990;183-204
26. Nagayama M, Yukito S, Nagayama T.Lipoprotein(a) and ischemic
cerebrovascular disease in young adult. Stroke. 1994:25; 74-8
27. Uterman G. The misteri of lp(a). Science. 1989:246; 904-10
28. Shahid HS. Serum high-sensitivity C-reactive protein and lipoprotein(a)
levels: a comparison between diabetic and non-diabetic patients with
coronary artery disease. Med J Malaysia. 2011: 66; 113-116
29. Hasnat MA, Islam Aemm, Chowdhury AW, Khan Hilr, Hosan MZ. High
sensitivity
C-reactive
protein
(hs-CRP)
and
its
correlation
with
angiographic severity of patient with coronary artery disease. J Dhaka
Med Coll. 2010:19; 91-97
30. Jalali BA, Rafie M, Mozaffari H. Lipoprotein(a) as a strong risk factor for
coronary artery disease in iranian population. Medical Journal of Islamic.
2000:13; 5-9
31. Achar SA, Kundu S, Norcross WA. Diagnosis of acute coronary
syndrome. American Family Physician 2005:72(01); 119-126
Universitas Sumatera Utara
32. Bucova M and Nikolitsa Pappa. C - Reactive protein, cytokines and
inflammation in cardiovascular disease. Bratis1 Lek Listy. 2008:109; 33340
33. Eleni S. Nakou ES, Evangelos N. Liberopoulos et al. The role of Creactive protein in atherosclerotic cardiovascular disease: an overview.
Current Vascular Pharmacology. 2008:6;258-70
34. McGill HC, McMahan CA, Herderick EE, Malcom GT, Tracy RE, Strong
JP. (2000). Origin of atherosclerosis in childhood and adolescence. Am J
Clin Nutr. 2000:72; 1307S-15S
35. Desideri G, De Simone M et al. Early activation of endothelial cells and
platelets in obesitas children. J Clin Endocrinol Metab. 2005:90; 3145-52
36. Kavazarakis E, Moustaki M, Gourgiotis D. The impact of serum lipid
levels on circulating soluble adhesion molecules in childhood. Pediatr
Res. 2002:52; 454-8
37. Koenig W. C-reactive protein and cardiovascular risk: an update on what
is going on in cardiology. Nephrol Dial Transplant. 2003:18; 1039–41
38. Wangko LC, Budiono B, Lefrandt RL. Angiografi koroner indikasi,
kontraindikasi, dan proteksi terhadap radiasi. J Biomedik. 2012;4(3)
Abstrak
39. Scanu AM. Structural and functional polymorphism of lipoprotein(a)
biological and clinical implications. Clinical Chemistry. 1995:41(1);170-2.
NACB Symposium
40. Hajjar KA, Nachman RL. The role of lipoprotein(a) in atherogenesis and
thrombosis. Anna Rev Med.1996
Universitas Sumatera Utara
41. Butman BT, Taddei-Peters WC, Ransom JH.
Lipoprotein(a)
as a
marker for atherosclerotic disease. Clinical Hemostasis review. 1993
42. Scanu AM, Fless GM. Lipo (a) heterogenicity and biological relevance. J
clinical Invest. 1990:85; 1709-15
43. Berg K. Lp(a) Lipoprotein : an overview, In : Scanu AM. Lipoprotein(a).
Academic press inc. San Diego,Toronto.Tokyo. 1990; 1-20
44. Ridker PM. Plasma concentration of lipoprotein and the risk of
future.Stroke. JAMA. 1995; 273
45. Scanu AM. Lipoprotein(a) and atherosclerosis. Annals of Internal
Med.1991:115; 209-18
46. Scott J. Lipoprotein(a) Thrombotic and atherogenic. BMJ. 1995:303; 6634
47. Galton J, Krone W. Hyperlipidaemia in Practice. Gower Medical
Publishing. London. 8-9.1991
48. Borque L. Automated Latex Nephelometric Immunoassay for the
Measurement of Serum Lipoprotein(a). Journal Clin Lab Anal. 1993: 7(2);
105-10
49. William RH. Radioimmunoassay of human plasma Lp(a) lipoprotein.
Journal of Lipid Research. 1997:18; 331-338
50. Nguyen TT. Predictive value of electrophoretically detected lipoprotein(a)
for coronary heart disease and cerebrovascular disease in a communitybased cohort of 9936 men and women. Circulation. 1997:96; 1390-1397.
51. Torres MB.Rapid Detection of Elevated Serum Lipoprotein(a) Levels :
Aubiodot Lp(a). Medical Education Cooperation with Cuba. 2000
Universitas Sumatera Utara
52. Stanley J. Instrumentation. In : Stanley J (eds). Essentials of
Immunology & Serology. Thomson Delmar Learning. Columbia. 2002;
133-48
53. Libby P, Ridker PM. Inflammation and atherosclerosis: role of creactive
protein in risk assessment. Am J Med. 2004:116; 9-16
54. Vermeire S,Van Assche G,Rutgeerts P. C-reactive protein as a marker
for inflammatory bowel disease. Inflammatory Bowel Diseases. 2004:10;
661-5.
55. Meier-Ewert HK, Ridker PM, Rifai N. Absence of diurnal variation of
Creactive protein concentrations in healthy human subjects.Clin Chem.
2001:47; 426–430
56. Gotschlich E. C-reactive protein: a historical overview. Annals of the New
York Academy of Sciences. 1989:557; 9-18.
57. Zakynthinos E, Pappa N. Inflammatory biomarkers in coronary artery
disease. Journal of Cardiology. 2009:53; 317-33
58. Danesh J, Pepys MB. C-Reactive protein and coronary disease: is there
a causal link?. Circulation. 2009:120; 2036-39
59. Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB . C-reactive
protein and coronary heart disease: a critical review. J Intern Med. 2008:
264; 295–314
60. Ridker P, Rifai N, Rose L. Comparison of c-reactive protein and lowdensity
lipoprotein
cholesterol
levels
in
the
prediction
of
first
cardiovascular events. The New England Journal of Medicine. 2002:
347(20); 1557-65.
Universitas Sumatera Utara
61. Delanghe J, Langlois M, De Bacquer D. Discriminative value of serum
amyloid A and other acute-phase proteins for coronary heart disease.
Atherosclerosis. 2002:160(2); 471-6
62. Pearson TA, George A. Mensah. Markers of inflammation and
cardiovascular disease. application to clinical and public health practice a
statement for healthcare professionals from the centers for disease
control and prevention and the american heart association. aha/cdc
scientific statement. Circulation. 2003:107; 499-511.
63. Handojo Indro. Immunoassay Terapan pada Beberapa Penyakit Infeksi.
Ed 1, Airlangga University Press, Surabaya, 2004; 272-285
64. Loho T. Pemeriksaan laboratorium pada stroke. Dalam: Pendidikan
Berkesinambungan Patologi Klinik, ed 1. Penerbit FKUI. 2008; 57-70
65. Henry JB. Clinical Diagnosis and Management by Laboratory Methods,
ed 20, Saunders. Philadelphia. 2001; 259-262
66. Roche. Roche Diagnostic GmbH. CRP. Product Information. 2003
67. Tietz. Clinical Chemistry and Molecular Diagnostics, ed 4. Saunders
Missouri. 2006; 543-546
68. Nyandak T, Gogna A, Bansal S, Deb M. High Sensitive C-Reactive
Protein (hsCRP) and its Correlation with Angiographic Severity of
Coronary Artery Disease (CAD). JIACM. 2007;8(3):217-21
69. Tanuwidjojo S. Recent development in pathogenesis of atherosclerosis.
Dalam: Tanuwidjojo S, Rifqi S. Atherosklerosis From Theory to Clinical
Practice, Naskah lengkap Cardiology-Update, 2003 p13-18
Universitas Sumatera Utara
70. Dwitaryo AB. Endotelium: Target Terapi untuk Penyakit Kardiovaskuler.
Dalam : Tanuwidjojo S, Rifqi S. Atherosclerosis From Theory to Clinical
Practice, Naskah lengkap Cardiology-Update Semarang, 2003 : p71-81
71. Soeharto I. Penyakit Jantung Koroner dan Serangan Jantung. Jakarta:
PT. Gramedia Pustaka Utama; 2004: 61-62
72. Heart-health screenings. American heart association [Internet]. 2011.
[cited 2013 Okt 3]. Available from:
http://www.heart.org/HEARTORG/Conditions/Heart-Health
Screenings_UCM_428687_Article.jsp#.TxegnNUqt0c
73. Price SA. Penyakit aterosklerotik koroner. Dalam: Wijaya C editor.
Patofisiologi Konsep Klinis Proses-Proses Penyakit. Edisi 4. Jakarta:
Penerbit buku kedokteran EGC; 1994:528-556
74. Coronary heart disease risk factors. National Heart Lung and Blood
Institute [Internet]. 2011. [cited 2011 Dec 14]. Available from:
http://www.nhlbi.nih.gov/health/health-topics/topics/hd/atrisk.html
75. Adam JMF . Manfaat penurunan Berat Badan pada Obese dengan
komplikasi Metabolik. Dalam: Djokomoeljanto R, Darmono, Suhartono T,
Pambayun
TGD
PERSADIA dan
editor.
Naskah
Lengkap
Kongres
Nasional
V
PITPERKENI. Semarang: Badan Penerbit UNDIP;
2002: 15-24
76. Patel VB, Robbins MA, Topol EJ. C-reactive protein: A ‘golden marker’
for inflammation and coronary artery disease. Cleveland Clinic J of
Medicine 2001;6(68):521-534.
Universitas Sumatera Utara
77. Azita F, Toba K, Asghar Z. et al. Comparison of lipoprotein(a) and
apolipoproteins in Children with and without familial history of premature
coronary artery disease. Iran J Pediatr, 2008;18 (2):159-162
78. Dutta J, Solankiz US. Lipoprotein(a) and lipid levels in children with
andwithout family history of premature ischemic heartdisease. World
Journal of Pharmacy and Pharmaceutical Sciences,2013; 2 (6): 58115819
79. Murat SN, Karadeniz M, Akyel A, et al. Relationship of high-sensitive Creactive protein with cardiovascular risk factors, clinical presentation and
angiographic profile in patients with acute coronary syndrome: An Indian
perspective. Indian heart journal.2013; 165 : 357-367
80. Cowie, M.R., Dar, Q. The Epidemiologyand Diagnosis of Heart Failure.
In: Fuster,V., et al., eds. Hurst’s the Heart. 12th ed.Volume 1. USA:
McGraw-Hill, 2008: 713
81. Yuliani F, Oenzil F, Iryani D. Hubungan berbagai faktor risiko terhadap
kejadian penyakit jantung koroner pada penderita diabetes mellitus tipe
2. Artikel Penelitian.Jurnal Kesehatan Andalas.2014; 3(1): 37-40
82. Ghodke SS, Padalkar RK, Bhagat SS, Ghone RA, Patil SM. hs- CRP: A
“Golden Marker” of Inflammation and Coronary Artery Disease.
International Journal of Health Sciences & Research. 2012; 2 (6): 42-46
83. Farhan HA, Al-Safar HB. Coronary Artery Disease: Conventional
RiskFactors & Angiographic Findings Among Young Iraqi Adults: Journal
ofBabel; 2010:2:644-650
Universitas Sumatera Utara
84. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease:
risk
factor,
paradox,
and
impact
of
weight
loss.J
Am
Coll
Cardiol.2009;53(21):1925-1932.
85. Jin J. Obesity and the Heart, The definition of obesity is based on body
mass index (BMI),a number calculated from a person’s height and
weight.JAMA. 2013; 310 (19): 2113
86. Karadeniz M, Murat SN, Relationship of high-sensitive C-reactive protein
withcardiovascular risk factors, clinical presentation andangiographic
profile in patients with acute coronarysyndrome: An Indian perspective.
Indian Heart Journal.2013; 65: 357-367
Universitas Sumatera Utara